Live feed08:00:00·52dPRReleasevia QuantisnowNew IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026ByQuantisnow·Wall Street's wire, on your screen.ALT· Altimmune Inc.Health Care
